65th Annual Meeting of American Society for Radiation Oncology
1st–4th October, 2023
San Diego Convention Center, San Diego, CA, USA
Nanobiotix will be presenting (oral presentation) the final readout on primary objectives from Study 102 Dose Expansion—the expansion part of a phase I dose escalation and dose expansion study evaluating potential first-in-class radioenhancer NBTXR3 for elderly patients with locally advanced head and neck cancer.
This oral presentation at ASTRO will be followed by a conference call on Thursday, October 5, 2023, at 8:00 AM EDT / 2:00 PM CEST. During the call, Laurent Levy, chief executive officer, will review the final Study 102 data before taking questions from participants.
Novel Radioenhancer NBTXR3 Activated by Radiotherapy in Cisplatin-ineligible Locally Advanced HNSCC Patients: Final Results of a Phase 1 Trial
Date/Time: Wednesday, October 4, 2023, 12:00 PM PT
Session: Head and Neck — Augmenting the Potential of Radiation Therapy with Novel Therapeutics and Imaging
Presenter: Dr. Christophe Le Tourneau, Institut Curie, Paris
Location: Room 1, San Diego Convention Center, San Diego, California